Physician profile
Bryant E Poole
NPI 1801869391
$3,040.81
in general payments reported to CMS, 2019-2025
36 companies · $266 in 2025
The $266 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $582 · 2021: $576 · 2022: $392 · 2023: $246 · 2024: $112 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $589 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.52 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $656.27 | 2019-2022 | |
| Astellas Pharma US INC | $586.05 | 2019-2025 | Myrbetriq, Xtandi |
| Pfizer INC. | $237.12 | 2019-2023 | |
| Antares Pharma, INC. | $224.28 | 2020-2023 | Tlando, Nocdurna, Xyosted |
| Novartis Pharmaceuticals Corporation | $189.65 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.22 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $122.05 | 2025 | Provenge |
| Allergan, INC. | $105.75 | 2020 | |
| Halozyme INC | $78.61 | 2023 | |
| Sumitomo Pharma America, INC. | $66.88 | 2024 | Orgovyx |
| Merck Sharp & Dohme LLC | $65.78 | 2020-2025 | Lynparza |
| Blue Earth Diagnostics | $62.81 | 2019-2023 | |
| Amgen INC. | $51.21 | 2019-2021 | |
| Boston Scientific Corporation | $45.21 | 2024 | Spaceoar Vue System - 10ml |
| Genzyme Corporation | $44.66 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $38.17 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $33.75 | 2021 | |
| Endo Pharmaceuticals INC. | $32.27 | 2019 | |
| Medtronic, INC. | $28.00 | 2021-2023 | Interstim |
| Tolmar Pharmaceuticals, INC. | $23.83 | 2022 | |
| Cook Medical LLC | $20.15 | 2025 | Cook |
| 180 Medical, INC. | $19.53 | 2022 | |
| Exelixis INC. | $17.35 | 2019 | |
| Seagen INC. | $15.52 | 2022 | |
| Becton, Dickinson and Company | $15.10 | 2025 | Arista |
| Abbvie INC. | $14.72 | 2022 | |
| Eisai INC. | $14.16 | 2019 | |
| Travere Therapeutics, INC. | $13.95 | 2020-2021 | |
| Axonics, INC. | $13.76 | 2023 | Axonics |
| Allegis Pharmaceuticals, LLC | $12.74 | 2023 | Urimar-T Caps |
| Emd Serono, INC. | $12.53 | 2020 | |
| Mission Pharmacal Company | $11.67 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryant Poole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.